Regulatory T Cells
Submission Deadline: 30 Apr 2023
Guest Editor
College of Veterinary Medicine, Long Island University, Brookville, NY, USA;Division of Regenerative Medicine, Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, USA
Interests: regulatory T cells; adult stem cells; vitamin D; retinoic acid; multiple sclerosis; inflammatory bowel disease; type 1 diabetes
Special Issue Information
Dear Colleagues,
Recent advances in the study of regulatory T cells (Tregs) highlight their essential role in maintaining the immune system's homeostasis and treating autoimmune diseases, transplantation rejection, cancers, and microbial infections. Tregs can be found in CD4+ and CD8+ T cell populations. While Treg's clinical trials are ongoing, there are still many challenges in their clinical application. Therefore, continued research is necessary to understand better their mechanisms of action and potential for clinical translation. Accordingly, this special issue will focus on all aspects related to Tregs. I hope that this platform will provide an opportunity for scientists to contribute their new findings and innovative concepts, which will eventually improve the application of Tregs in treating diseases in humans and animals. Both original articles and reviews are welcome. Examples of covered topics include but are not limited to:
• CD4+ Tregs.
• CD8+ Treg.
• Genetically engineered Tregs, such as CAR Tregs.
I encourage you to send me an abstract as soon as possible, especially for those who want to contribute a review. The manuscripts will be reviewed when they are received. If accepted, they will be published immediately and appear on the homepage of this special issue.
Dr. Xiaolei Tang
Guest Editor
Keywords
- regulatory T cells
- genetically engineered Tregs
- CD4+ Tregs
- CD8+ Tregs
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Paper (1)
Higher Expression of Activated CD8+ T Lymphocytes (CD8+CD25+, CD8+CD69+ and CD8+CD95+) Mediate Early Post-Transplant Acute Tubular Injury in Kidney Recipients
Front. Biosci. (Landmark Ed) 2023, 28(6), 119; https://doi.org/10.31083/j.fbl2806119
(This article belongs to the Special Issue Regulatory T Cells)